Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy
- 654 Downloads
Denosumab, a novel monoclonal antibody that targets the receptor activator of nuclear factor-κB (RANK) ligand (RANKL), has recently been used to treat patients with giant cell tumor of bone (GCTB). However, few reports have described the clinical results of denosumab therapy for spinal GCTB and evaluated treatment efficacy with respect to the entirety of the resected vertebra after denosumab therapy.
We present the case of a 51-year-old man with T12 GCTB that was completely removed by a total spondylectomy following 10 courses of neoadjuvant denosumab therapy. Post-therapy radiological findings indicated epidural tumor reduction in the spinal canal and sclerotic rim formation. However, the affected vertebra collapsed despite denosumab therapy and a massive bridging callus formation was present between the spinal GCTB and adjacent vertebra.
These morphological changes made the tumor margins unclear and increased the difficulty of dissection of the segmental arteries from the vertebral body and en bloc corpectomy by a posterior-approach. Pathological findings indicated increased woven bone at the peripheral lesion of the resected vertebra and RANKL-positive stromal cells remained around the woven bone.
These findings support that GCTB stromal cells survived around the newly formed woven bone after long-term denosumab treatment and total surgical resection of such primary spinal lesions as the gold-standard treatment, even following administration of denosumab. Surgeons should note that prolonged adjuvant denosumab therapy may increase the difficulty of performing a posterior-approach total en bloc spondylectomy.
KeywordsGiant cell tumor Denosumab Total spondylectomy Spine RANKL
The authors thank Yoshikazu Tanzawa for the patient referral and provision biopsy specimen.
Compliance with ethical standards
Conflict of interest
The authors report no conflict of interest concerning the materials or methods used in the study or the findings specified in this paper.
Supplementary material 1 (MP4 456086 kb)
- 4.Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I (2013) Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 14(9):901–908. doi: 10.1016/S1470-2045(13)70277-8 CrossRefPubMedGoogle Scholar
- 6.Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA (2015) Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol 22(9):2860–2868. doi: 10.1245/s10434-015-4634-9 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Randhawa SS, Kwan AK, Chiu CK, Chan CY, Kwan MK (2016) Neurological recovery in two patients with cauda equina syndrome secondary to L5 lumbar spine giant cell tumour after treatment with denosumab without surgery. Asian Spine J 10(5):945–949. doi: 10.4184/asj.2016.10.5.945 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Agarwal A, Larsen BT, Buadu LD, Dunn J, Crawford R, Daniel J, Bishop MC (2013) Denosumab chemotherapy for recurrent giant-cell tumor of bone: a case report of neoadjuvant use enabling complete surgical resection. Case Rep Oncol Med 2013:496351. doi: 10.1155/2013/496351 PubMedPubMedCentralGoogle Scholar